SAN DIEGO, Oct. 20 /PRNewswire-FirstCall/ -- Genetronics Biomedical Corporation , a late stage developer of oncology and other therapies using electroporation to deliver drugs, nucleic acids, and genes, announced today that the Company's President and CEO, Dr. Avtar Dhillon, will present a corporate overview on the Company at the Rodman & Renshaw Techvest 6th Annual Global Healthcare Conference on Tuesday, October 26th at 11:10 a.m. Eastern Time (8:10 a.m. Pacific Time). The conference will be held at the Waldorf Astoria in New York City from October 26-28, 2004.
A live webcast of the presentation will be available on the Company's website at http://www.genetronics.com/ and will be archived there for 30 days following the conclusion of the broadcast. Please connect to Genetronics' website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.
About Genetronics Biomedical Corporation
Genetronics Biomedical Corporation is a late stage biomedical company focused on building an oncology franchise based on its proprietary electroporation therapy. The therapy targets a significant unmet clinical need: the selective killing of cancer cells and local ablation of solid tumors while preserving healthy tissue. The company is moving its lead product, the MedPulser(R) Electroporation Therapy System, through pre-marketing studies for head and neck cancer in Europe, where it has CE Mark accreditation, and a U.S. Phase III pivotal study for recurrent head and neck cancer. Merck, Vical, Chiron, the US Navy and other partners are also employing Genetronics' electroporation technology, which enhances local delivery of drugs and DNA, in their development of novel DNA vaccines and gene therapies. Genetronics is a leader in electroporation, with over 240 patents worldwide that are issued, allowed or pending. More information can be obtained at http://www.genetronics.com/.
This press release contains certain forward-looking statements relating to Genetronics' plans to develop its electroporation drug and gene delivery technology and to maximize shareholder value. Actual events or results may differ from Genetronics' expectations as a result of a number of factors, including the uncertainties inherent in clinical trials and product development programs, evaluation of potential opportunities, the level of corporate expenditures, the assessment of Genetronics' technology by potential corporate partners, and capital market conditions, and others set forth in the Genetronics Annual Report, on Form 10-K for the 12-month period ending December 31, 2003, and the Form 10-Q for the 3-month period ending June 30, 2004, and other regulatory filings. There can be no assurance that any product in the Genetronics product pipeline will be successfully developed or manufactured, or that final results of human pilot studies or clinical studies will be supportive of regulatory approvals required to market Licensed Products. The American Stock Exchange has not reviewed and do not accept responsibility for the adequacy or accuracy of this release.
Genetronics Biomedical Corporation
CONTACT: Investor Relations, Bernie Hertel of Genetronics BiomedicalCorporation, +1-858-410-3101; or Media Relations, Susan Neath of Atkins +Associates, +1-858-527-3486, for Genetronics Biomedical Corporation